Global Benign Prostatic Hyperplasia Treatment Market: Industry Analysis and Forecast (2020-2026)

Global Benign Prostatic Hyperplasia Treatment Market is expected to reach US$ XX Mn by 2026 from US$ XX Mn in 2019, at a CAGR of 5.2% during the forecast period.

Global Benign Prostatic Hyperplasia Treatment Market
Global Benign Prostatic Hyperplasia Treatment Market Overview:

Benign Prostatic Hyperplasia (BHP) is a medical condition, in which the prostate gland gets enlarged and commonly diagnosed in males. It is basically the non-cancerous growth of the gland developed from the prostate cell. The most common indications of these conditions are difficulties in initiating urine, frequent urination, and a weak urinary system.
Global Benign Prostatic Hyperplasia Treatment Market Dynamics:

Adaptation of unhealthy lifestyle is the key driver contributing to the market growth.

Other factors like the growing population of elderly men and family history encourage the market growth. About one-third of men experience moderate to severe symptoms by age 60, and about half do so by age 80 and heredity causes an increase in the risk of contracting BPH. As many as 14 million men in the United States have symptoms of BPH.

Worldwide, approximately 30 million men have symptoms related to BPH. Studies show that diabetes, as well as heart disease and the use of beta-blockers, might increase the risk of BPH, which in turn raises demand for the BPH treatment market. In addition, the growing health awareness and early diagnosis of the medical condition fuelling the demand for the treatment and propel the market growth. Along with this, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment stimulate the growth of the BPH treatment market.

However, the high price involving the benign prostatic hyperplasia treatment, expected to hamper the market growth. In addition to this, side effects associated with the BPH medications like dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis and apart from these some drugs also reduce the synthesis of several neuro-active steroids may impact negatively on the market growth.

The patent expiration of many products has paved the way for a new promising product pipeline high potential in untapped markets of the emerging economies is anticipated to provide lucrative growth opportunities for the market growth during the forecast years.

The report has profiled twenty-nine key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Global Benign Prostatic Hyperplasia Treatment Market Segment Analysis:

The global Benign Prostatic Hyperplasia Treatment market is segmented on the basis of Drug Type, Surgery Type and End-Users.

Based on Drug Type, the alpha-blockers segment is expected to hold a prominent market share over the forecast years. Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier. Alpha-blockers — which include alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo) — usually work quickly in men with relatively small prostates. In Japan, α1 blockers are recommended in the clinical guidelines for BPH as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH.

Nymox Pharmaceutical Corporation has developed NX-1207 (fexapotide triflutate), a novel compound that is administered transrectally. In July 2015, Nymox announced that its Phase III clinical study of NX-1207 had successfully met its primary endpoints. This injection lasts for a mean duration of 3.5 years after a single injection. The NX-1207 is considered to be safe as compared to existing treatments with minimal side effects.

Based on Surgery Type, the TURP (Transurethral resection of the prostate) segment is considered to be dominant over the forecast years. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A lighted scope is inserted into your urethra, and the surgeon removes all but the outer part of the prostate.

Owing to the growing trend, nowadays, TURP is being performed on an outpatient basis and selected patients are granted discharge within 24 hours of admission. Advantages associated with TURP such as less hospital stay and quick recovery encourage the segment to grow at a faster pace during the forecast period.

Global Benign Prostatic Hyperplasia Treatment Market

To know about the Research Methodology :- Request Free Sample Report
Global Benign Prostatic Hyperplasia Treatment Market Regional Insights:Global Benign Prostatic Hyperplasia Treatment Market Regional Insights

North America region is anticipated to hold the largest market share.

The high prevalence of BPH and other associated lower urinary tract symptoms present in the region is the major factor dominating the market in North America. Several studies in the past era have reported a significant percentage of men in the US, aged between 45 and 80 years suffer from some type of lower urinary tract symptoms and most have some form of BPH symptoms.

Collaboration of many hospitals with non-profit organization and companies in the US and Canada, contribute to raising awareness and adequate resources for the treatment of urological disorders. The American Medical Systems portfolio acquisition included the procurement of leading products for the treatment of a variety of urologic conditions, including the minimally invasive GreenLight XPS laser therapy system.

Asia-Pacific region is anticipated to grow at a faster pace during the forecast period, owing to a high population base, increase in disposable income, and enhanced patient awareness about the benign prostatic hyperplasia condition.

The report also helps in understanding the Global Benign Prostatic Hyperplasia Treatment Market dynamics, structure by analyzing the market segments and project the Global Benign Prostatic Hyperplasia Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Benign Prostatic Hyperplasia Treatment Market make the report investor’s guide.
Global Benign Prostatic Hyperplasia Treatment Market Key Developments:

• In August 2015, Boston Scientific completed its acquisition of American Medical Systems’ Male Urology Portfolio from Endo Pharmaceuticals for $1.6bn, with the potential for an additional $50m in milestone payments predicated on 2016 sales. As a result of this acquisition, Boston Scientific positioned itself as the market leader in laser-based surgery systems and an overall leader in urology with its comprehensive portfolio. The new business portfolio was combined with Boston Scientific’s Urology and Women’s Health businesses to create the new Urology and Pelvic Health business.

• The new handheld Rezūm device manufactured by NxThera, performs Prostate Convective WAVE ablation. This innovation is considered as a source of growth in the market for office-based thermotherapy for symptomatic BPH. The Rezūm device is expected to see an increase in sales over the forecast period.
Global Benign Prostatic Hyperplasia Treatment Market Scope: Inquire before buying

Global Benign Prostatic Hyperplasia Treatment Market

Global Benign Prostatic Hyperplasia Treatment Market, by Region

• North America
• Europe
• South America
Global Benign Prostatic Hyperplasia Treatment Market Key Players

• Boston Scientific Corporation
• Coloplast Group
• Teleflex Incorporated
• Olympus Corporation
• GlaxoSmithKline PLC
• Eli Lilly
• Pfizer, Inc.
• Abbott
• Asahi Kasei Corporation
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Allergan plc
• Alembic
• IPG Photonics Corporation
• Richard Wolf GmbH
• Unilab, Inc.
• Pharex Health Corporation
• Biolitec AG
• Urologix, LLC
• Advin Health Care
• Medifocus, Inc.
• Asclepion Laser Technologies GmbH
• Pnn Medical A/S
• Surgical Lasers Inc.
• Quanta Systems
• Allium Ltd.
• Lumenis Ltd.

For More Information Visit @:
 This Report Is Submitted By : Maximize Market Research Company        
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:    
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors

• SRS Medical


Leave a Reply

Your email address will not be published. Required fields are marked *

five × 3 =